[PDF][PDF] Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical …
RS Herbst, DF Bajorin, H Bleiberg, D Blum… - Journal of clinical …, 2006 - academia.edu
EXECUTIVE SUMMARY Clinical Cancer Advances 2005 is the first independent annual
review of the top advances in cancer treatment, screening, and prevention across all cancer …
review of the top advances in cancer treatment, screening, and prevention across all cancer …
[HTML][HTML] The gut microbiota: a potential gateway to improved health outcomes in breast cancer treatment and survivorship
K Sampsell, D Hao, RA Reimer - International Journal of Molecular …, 2020 - mdpi.com
Breast cancer is the most frequently diagnosed cancer in women worldwide. The disease
and its treatments exert profound effects on an individual's physical and mental health …
and its treatments exert profound effects on an individual's physical and mental health …
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2018 - Future Medicine
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2019 - Future Medicine
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients
with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received …
with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received …
[PDF][PDF] Pan Canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine …
B Melosky, H Anderson, RL Burkes, Q Chu… - J Clin …, 2016 - metaphase-consulting.com
Purpose Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with
advanced non–small-cell lung cancer (NSCLC) whose epidermal growth factor receptor …
advanced non–small-cell lung cancer (NSCLC) whose epidermal growth factor receptor …
[HTML][HTML] Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated …
JJ Laskin, G Nicholas, C Lee, B Gitlitz, M Vincent… - Journal of Thoracic …, 2012 - Elsevier
Purpose Clusterin (CLU), an antiapoptotic, stress-associated protein, confers resistance to
therapy when overexpressed. This trial tested custirsen (OGX-011), an inhibitor of CLU …
therapy when overexpressed. This trial tested custirsen (OGX-011), an inhibitor of CLU …
[HTML][HTML] Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment
D Hao, MO Sarfaraz, F Farshidfar, DG Bebb, CY Lee… - Metabolomics, 2016 - Springer
Lung cancer causes more deaths in men and women than any other cancer related disease.
Currently, few effective strategies exist to predict how patients will respond to treatment. We …
Currently, few effective strategies exist to predict how patients will respond to treatment. We …
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study
MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2020 - Future Medicine
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR
mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and …
mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and …
Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation
S Habbous, KP Chu, H Lau, M Schorr, M Belayneh… - Cmaj, 2017 - Can Med Assoc
BACKGROUND: The incidence of oropharyngeal cancer has risen over the past 2 decades.
This rise has been attributed to human papillomavirus (HPV), but information on temporal …
This rise has been attributed to human papillomavirus (HPV), but information on temporal …
[HTML][HTML] CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer
S Otsuka, AC Klimowicz, K Kopciuk, SK Petrillo… - Journal of Thoracic …, 2011 - Elsevier
Background It has been proposed that the chemokine receptor, CXCR4, and its ligand,
stromal cell-derived factor-1 (SDF-1), play a critical role in organ-specific tumor metastasis …
stromal cell-derived factor-1 (SDF-1), play a critical role in organ-specific tumor metastasis …